Nonsurgical Therapy for Early-Stage Lung Cancer

Megan E Daly; Patrick Beagen; Mohammad H Madani

doi:10.1016/j.hoc.2023.02.002

Nonsurgical Therapy for Early-Stage Lung Cancer

Hematol Oncol Clin North Am. 2023 Jun;37(3):499-512. doi: 10.1016/j.hoc.2023.02.002. Epub 2023 Apr 4.

Authors

Megan E Daly¹, Patrick Beagen², Mohammad H Madani³

Affiliations

¹ Department of Radiation Oncology, University of California Davis Comprehensive Cancer Center, 4501 X Street, G-140, Sacramento, CA 95817, USA. Electronic address: medaly@ucdavis.edu.
² Department of Radiation Oncology, University of California Davis Comprehensive Cancer Center, 4501 X Street, G-140, Sacramento, CA 95817, USA.
³ RadiologyDepartment of Radiology, University of California, Davis, 4860 Y Street, Suite 3100, Sacramento, CA 95817, USA.

PMID: 37024386
DOI: 10.1016/j.hoc.2023.02.002

Abstract

Treatment options for medically inoperable, early-stage non-small cell lung cancer (NSCLC) include stereotactic ablative radiotherapy (SABR) and percutaneous image guided thermal ablation. SABR is delivered over 1-5 sessions of highly conformal ablative radiation with excellent tumor control. Toxicity is depending on tumor location and anatomy but is typically mild. Studies evaluating SABR in operable NSCLC are ongoing. Thermal ablation can be delivered via radiofrequency, microwave, or cryoablation, with promising results and modest toxicity. We review the data and outcomes for these approaches and discuss ongoing studies.

Keywords: Non-small cell lung cancer; SABR; SBRT; Thermal ablation.

Publication types

Review

MeSH terms

Carcinoma, Non-Small-Cell Lung* / pathology
Humans
Hyperthermia, Induced*
Lung Neoplasms* / pathology
Neoplasm Staging
Radiosurgery* / methods